Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

medRxiv - Infectious Diseases Pub Date : 2024-09-06 DOI:10.1101/2024.09.04.24312992

RECOVERY Collaborative Group, Peter W Horby, Jonathan R Emberson, Louise Thwaites, Mark Campbell, Leon Peto, Guilherme Pessoa-Amorim, Natalie Staplin, Raph L Hamers, John Amuasi, Jeremy Nel, Evelyne Kestelyn, Nguyen Thanh Phong, Anil Shrestha, Nasronudin Nasronudin, Rahuldeb Sarkar, Pham Ngoc Thach, Damodar Patel, Uun Samardi, Richard Stewart, Erni Nelwan, Manisha Rawal, J Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Marion Mafham, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Buddha Basnyat, Richard Haynes, Martin J Landray

{"title":"Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial","authors":"RECOVERY Collaborative Group, Peter W Horby, Jonathan R Emberson, Louise Thwaites, Mark Campbell, Leon Peto, Guilherme Pessoa-Amorim, Natalie Staplin, Raph L Hamers, John Amuasi, Jeremy Nel, Evelyne Kestelyn, Nguyen Thanh Phong, Anil Shrestha, Nasronudin Nasronudin, Rahuldeb Sarkar, Pham Ngoc Thach, Damodar Patel, Uun Samardi, Richard Stewart, Erni Nelwan, Manisha Rawal, J Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Marion Mafham, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Buddha Basnyat, Richard Haynes, Martin J Landray","doi":"10.1101/2024.09.04.24312992","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Low-dose corticosteroids (e.g. 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with hypoxia but not receiving ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation), but the balance of efficacy and safety in patients receiving ventilatory support is uncertain.","PeriodicalId":501509,"journal":{"name":"medRxiv - Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24312992","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background Low-dose corticosteroids (e.g. 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with hypoxia but not receiving ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation), but the balance of efficacy and safety in patients receiving ventilatory support is uncertain.

查看原文本刊更多论文

需要呼吸支持的 COVID-19 住院患者使用大剂量皮质类固醇（RECOVERY）：一项随机对照、开放标签、平台试验

背景低剂量皮质类固醇（如 6 毫克地塞米松）已被证明可降低缺氧 COVID-19 患者的死亡率。我们以前曾报道过，大剂量皮质类固醇会对缺氧但未接受通气支持（无创机械通气、有创机械通气或体外膜氧合）的患者造成伤害，但在接受通气支持的患者中，疗效与安全性之间的平衡尚不确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

medRxiv - Infectious Diseases

自引率

0.00%

发文量